MANGOCEUTICALS, INC. (MGRX): Submission of Matters to a Vote of Security Holders
MANGOCEUTICALS, INC. (MGRX) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.07. Submission of Matters to a Vote of Security Holders. On November 2, 2026, the holder of all 50 issued and outstanding shares of Series B Convertible Preferred Stock (the “ Series B Preferred Stock ”) of Mangoceuticals, Inc. (the “ Company ”), acting by written consent
How this was made
The 30-second read
Why it matters
The filing introduces a modest $10 M raise that could dilute existing shareholders but also provide needed funding for development. Market reaction will depend on perceived use of proceeds and likelihood of closing.
Market read
A primary‑source filing for a small capital raise; limited trading relevance beyond the stock itself.
What to watch
Regulation A exemption may allow broader retail participation, potentially supporting price if demand is strong.
Background
Mangoceuticals is a micro‑cap biotech that previously issued Series B convertible preferred stock. The 8‑K details a new Series D preferred issuance subject to shareholder approval and SEC qualification.
Ticker impact
Mangoceuticals filed an 8‑K announcing a proposed $10 million Regulation A offering of 1 million Series D preferred shares at $10 each, pending approval.
likely downward pressure as market prices in dilution risk
The offering is not yet effective and could be cancelled, but if proceeded it adds $10 M of equity and up to 1 M new shares, diluting existing holders.
Market effects
Limited impact on the broader biotech/health‑care sector; mainly a micro‑cap financing event.
No significant regional effect; confined to the company's shareholders.
Minimal global relevance.
Counterpoint
If the capital is used for a breakthrough product, the dilution could be offset by future upside.
Key entities
- companyMangoceuticals, Inc.
Issuer of the proposed Series D preferred stock.
- personJacob D. Cohen
Chief Executive Officer who signed the filing.
